- Home
- ASIC vs GPCR Comparison
ASIC vs GPCR Comparison
Compare ASIC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIC
- GPCR
- Stock Information
- Founded
- ASIC 2018
- GPCR 2016
- Country
- ASIC United States
- GPCR United States
- Employees
- ASIC N/A
- GPCR N/A
- Industry
- ASIC Property-Casualty Insurers
- GPCR
- Sector
- ASIC Finance
- GPCR
- Exchange
- ASIC Nasdaq
- GPCR Nasdaq
- Market Cap
- ASIC 1.0B
- GPCR 1.1B
- IPO Year
- ASIC 2025
- GPCR 2023
- Fundamental
- Price
- ASIC $22.64
- GPCR $19.61
- Analyst Decision
- ASIC Strong Buy
- GPCR Strong Buy
- Analyst Count
- ASIC 4
- GPCR 9
- Target Price
- ASIC $27.00
- GPCR $75.63
- AVG Volume (30 Days)
- ASIC 119.5K
- GPCR 898.3K
- Earning Date
- ASIC 08-11-2025
- GPCR 08-06-2025
- Dividend Yield
- ASIC N/A
- GPCR N/A
- EPS Growth
- ASIC N/A
- GPCR N/A
- EPS
- ASIC 0.15
- GPCR N/A
- Revenue
- ASIC $378,302,000.00
- GPCR N/A
- Revenue This Year
- ASIC $13.81
- GPCR N/A
- Revenue Next Year
- ASIC $46.67
- GPCR N/A
- P/E Ratio
- ASIC $147.57
- GPCR N/A
- Revenue Growth
- ASIC 42.48
- GPCR N/A
- 52 Week Low
- ASIC $18.50
- GPCR $13.22
- 52 Week High
- ASIC $25.30
- GPCR $45.37
- Technical
- Relative Strength Index (RSI)
- ASIC N/A
- GPCR 56.57
- Support Level
- ASIC N/A
- GPCR $18.39
- Resistance Level
- ASIC N/A
- GPCR $21.44
- Average True Range (ATR)
- ASIC 0.00
- GPCR 1.18
- MACD
- ASIC 0.00
- GPCR 0.31
- Stochastic Oscillator
- ASIC 0.00
- GPCR 67.60
About ASIC Ategrity Specialty Insurance Company Holdings Common Stock
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.